Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1+ leukemias

E Doubrovina, T Carpenter, D Pankov… - Blood, The Journal …, 2012 - ashpublications.org
E Doubrovina, T Carpenter, D Pankov, A Selvakumar, A Hasan, RJ O'Reilly
Blood, The Journal of the American Society of Hematology, 2012ashpublications.org
The Wilms tumor protein (WT-1) is widely recognized as a tumor antigen that is expressed
differentially by several malignancies. However, WT-1 peptides known to induce tumoricidal
T cells are few. In the present study, we evaluated T-cell responses of 56 healthy donors to
in vitro sensitization with autologous APCs loaded with a pool of overlapping 15-mer
peptides spanning the sequence of WT-1. Thereafter, we mapped the WT-1 peptides
eliciting responses in each individual, defined the immunogenic peptides, and identified …
Abstract
The Wilms tumor protein (WT-1) is widely recognized as a tumor antigen that is expressed differentially by several malignancies. However, WT-1 peptides known to induce tumoricidal T cells are few. In the present study, we evaluated T-cell responses of 56 healthy donors to in vitro sensitization with autologous APCs loaded with a pool of overlapping 15-mer peptides spanning the sequence of WT-1. Thereafter, we mapped the WT-1 peptides eliciting responses in each individual, defined the immunogenic peptides, and identified their presenting HLA alleles. We report 41 previously unreported epitopes of WT-1: 5 presented by class II and 36 by class I alleles, including 10 that could be presented by more than 1 class I allele. IFNγ+ T cells responding to 98% of the class I and 60% of the class II epitopes exhibited HLA-restricted cytotoxicity against peptide-loaded targets. T cells specific for 36 WT-1 peptides were evaluable for leukemocidal activity, of which 27 (75%) lysed WT-1+ leukemic targets sharing their restricting HLA allele. Each epitope identified induced T-cell responses in most donors sharing the epitopes' presenting allele; these responses often exceeded responses to flanking peptides predicted to be more immunogenic. This series of immunogenic epitopes of WT-1 should prove useful for immunotherapies targeting WT-1+ malignancies.
ashpublications.org